Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Jacob Siedner, M.D.

Co-Author

This page shows the publications co-authored by Mark Siedner and Suzanne McCluskey.
Connection Strength

4.033
  1. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021 12 15; 35(Suppl 2):S127-S135.
    View in: PubMed
    Score: 0.975
  2. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013. AIDS Patient Care STDS. 2018 07; 32(7):257-264.
    View in: PubMed
    Score: 0.768
  3. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. J Acquir Immune Defic Syndr. 2017 10 01; 76(2):183-187.
    View in: PubMed
    Score: 0.729
  4. Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa. HIV Med. 2022 May; 23(5):474-484.
    View in: PubMed
    Score: 0.242
  5. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Ann Intern Med. 2021 12; 174(12):1683-1692.
    View in: PubMed
    Score: 0.242
  6. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. AIDS. 2021 06 01; 35(7):1083-1089.
    View in: PubMed
    Score: 0.235
  7. Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models. J Med Econ. 2020 Mar; 23(3):221-227.
    View in: PubMed
    Score: 0.213
  8. Management of Virologic Failure and HIV Drug Resistance. Infect Dis Clin North Am. 2019 09; 33(3):707-742.
    View in: PubMed
    Score: 0.205
  9. Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa? J Acquir Immune Defic Syndr. 2017 10 01; 76(2):188-192.
    View in: PubMed
    Score: 0.182
  10. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. HIV Clin Trials. 2017 07; 18(4):149-155.
    View in: PubMed
    Score: 0.180
  11. Drug resistance and use of long-acting ART. Lancet HIV. 2022 Mar 28.
    View in: PubMed
    Score: 0.062
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.